Abstract

Propofol infusion syndrome is a rare but extremely dangerous complication of propofol administration. Certain risk factors for the development of propofol infusion syndrome are described, such as appropriate propofol doses and durations of administration, carbohydrate depletion, severe illness, and concomitant administration of catecholamines and glucocorticosteroids. The pathophysiology of this condition includes impairment of mitochondrial beta-oxidation of fatty acids, disruption of the electron transport chain, and blockage of beta-adrenoreceptors and cardiac calcium channels. The disease commonly presents as an otherwise unexplained high anion gap metabolic acidosis, rhabdomyolysis, hyperkalemia, acute kidney injury, elevated liver enzymes, and cardiac dysfunction. Management of overt propofol infusion syndrome requires immediate discontinuation of propofol infusion and supportive management, including hemodialysis, hemodynamic support, and extracorporeal membrane oxygenation in refractory cases. However, we must emphasize that given the high mortality of propofol infusion syndrome, the best management is prevention. Clinicians should consider alternative sedative regimes to prolonged propofol infusions and remain within recommended maximal dose limits.

Highlights

  • Propofol is a sedative-hypnotic medication commonly used as an induction agent for preoperative sedation, prior to endotracheal intubation and other procedures as well as for sedation in the intensive care unit [1]

  • Its use was approved by the food and drug administration (FDA) in November 1989

  • In 1996, the first adult case of lactic acidosis associated with propofol administration was reported [6]

Read more

Summary

Introduction

Propofol is a sedative-hypnotic medication commonly used as an induction agent for preoperative sedation, prior to endotracheal intubation and other procedures as well as for sedation in the intensive care unit [1]. The first reported death associated with propofol infusion was of a 3-year-old girl in Denmark in 1990 [3]. This patient developed high anion gap metabolic acidosis (HAGMA), hypotension, and polyorgan failure [3]. In 1992 Parke et al reported the deaths of five children who had similar presentations to the Danish case while being on propofol infusion [4]. In 1996, the first adult case of lactic acidosis associated with propofol administration was reported [6]. In 1998 a first adolescent mortality associated with propofol use was reported in a 17-year-old male with refractory status epilepticus [7]. We will finish with the discussion of its prevention and the treatment for established PRIS

Pathophysiology of Propofol Infusion Syndrome
Epidemiology of the Propofol Infusion Syndrome
Clinical Presentation and Diagnosis of Propofol Infusion Syndrome
Treatment of Established Propofol Infusion Syndrome
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call